Literature DB >> 31076443

Patrolling monocytes scavenge endothelial-adherent sickle RBCs: a novel mechanism of inhibition of vaso-occlusion in SCD.

Yunfeng Liu1, Hui Zhong1, Weili Bao1, Avital Mendelson1, Xiuli An1, Patricia Shi1, Stella T Chou2, Deepa Manwani3, Karina Yazdanbakhsh1.   

Abstract

Painful vaso-occlusive crisis (VOC) is the most common complication of sickle cell disease (SCD). Increasing evidence suggests that vaso-occlusion is initiated by increased adherence of sickle red blood cells (RBCs) to the vascular endothelium. Thus, the mechanisms that remove endothelial-attached sickle RBCs from the microvasculature are expected to be critical for optimal blood flow and prevention of VOC in SCD. We hypothesized that patrolling monocytes (PMos), which protect against vascular damage by scavenging cellular debris, could remove endothelial-adherent sickle RBCs and ameliorate VOC in SCD. We detected RBC (GPA+)-engulfed material in circulating PMos of patients with SCD, and their frequency was further increased during acute crisis. RBC uptake by PMos was specific to endothelial-attached sickle, but not control, RBCs and occurred mostly through ICAM-1, CD11a, and CD18. Heme oxygenase 1 induction, by counteracting the cytotoxic effects of engulfed RBC breakdown products, increased PMo viability. In addition, transfusions, by lowering sickle RBC uptake, improved PMo survival. Selective depletion of PMos in Townes sickle mice exacerbated vascular stasis and tissue damage, whereas treatment with muramyl dipeptide (NOD2 ligand), which increases PMo mass, reduced stasis and SCD associated organ damage. Altogether, these data demonstrate a novel mechanism for removal of endothelial attached sickle RBCs mediated by PMos that can protect against VOC pathogenesis, further supporting PMos as a promising therapeutic target in SCD VOC.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2019        PMID: 31076443      PMCID: PMC6695561          DOI: 10.1182/blood.2019000172

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  74 in total

Review 1.  Erythrocyte adhesion in sickle cell disease.

Authors:  Leslie V Parise; Marilyn J Telen
Journal:  Curr Hematol Rep       Date:  2003-03

2.  Monocyte phagocytic activity in sickle cell disease.

Authors:  E Mendoza; N Gutgsell; J D Temple; P Issitt
Journal:  Acta Haematol       Date:  1991       Impact factor: 2.195

3.  Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease.

Authors:  Stéphane M Camus; João A De Moraes; Philippe Bonnin; Paul Abbyad; Sylvain Le Jeune; François Lionnet; Laurent Loufrani; Linda Grimaud; Jean-Christophe Lambry; Dominique Charue; Laurent Kiger; Jean-Marie Renard; Claire Larroque; Hervé Le Clésiau; Alain Tedgui; Patrick Bruneval; Christina Barja-Fidalgo; Antigoni Alexandrou; Pierre-Louis Tharaux; Chantal M Boulanger; Olivier P Blanc-Brude
Journal:  Blood       Date:  2015-03-31       Impact factor: 22.113

4.  Patrolling the endothelium in sickle cell disease.

Authors:  Victor R Gordeuk
Journal:  Blood       Date:  2018-04-05       Impact factor: 22.113

5.  Abnormal adherence of sickle erythrocytes to cultured vascular endothelium: possible mechanism for microvascular occlusion in sickle cell disease.

Authors:  R P Hebbel; O Yamada; C F Moldow; H S Jacob; J G White; J W Eaton
Journal:  J Clin Invest       Date:  1980-01       Impact factor: 14.808

6.  Human monocytes CD36 and CD16 are signaling molecules. Evidence from studies using antibody-induced chemiluminescence as a tool to probe signal transduction.

Authors:  C Trezzini; T W Jungi; M O Spycher; F E Maly; P Rao
Journal:  Immunology       Date:  1990-09       Impact factor: 7.397

7.  Heme oxygenase-1 modulates the expression of adhesion molecules associated with endothelial cell activation.

Authors:  Miguel P Soares; Mark P Seldon; Isabel Pombo Gregoire; Tatiana Vassilevskaia; Pascal O Berberat; Jia Yu; Tung-Yu Tsui; Fritz H Bach
Journal:  J Immunol       Date:  2004-03-15       Impact factor: 5.422

Review 8.  Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.

Authors:  Barbara P Yawn; George R Buchanan; Araba N Afenyi-Annan; Samir K Ballas; Kathryn L Hassell; Andra H James; Lanetta Jordan; Sophie M Lanzkron; Richard Lottenberg; William J Savage; Paula J Tanabe; Russell E Ware; M Hassan Murad; Jonathan C Goldsmith; Eduardo Ortiz; Robinson Fulwood; Ann Horton; Joylene John-Sowah
Journal:  JAMA       Date:  2014-09-10       Impact factor: 56.272

9.  Adhesion of sickle red blood cells and damage to interleukin-1 beta stimulated endothelial cells under flow in vitro.

Authors:  M Natarajan; M M Udden; L V McIntire
Journal:  Blood       Date:  1996-06-01       Impact factor: 22.113

10.  Patrolling monocytes control tumor metastasis to the lung.

Authors:  Richard N Hanna; Caglar Cekic; Duygu Sag; Robert Tacke; Graham D Thomas; Heba Nowyhed; Erica Herrley; Nicole Rasquinha; Sara McArdle; Runpei Wu; Esther Peluso; Daniel Metzger; Hiroshi Ichinose; Iftach Shaked; Grzegorz Chodaczek; Subhra K Biswas; Catherine C Hedrick
Journal:  Science       Date:  2015-10-22       Impact factor: 47.728

View more
  11 in total

Review 1.  Molecular mechanisms of hepatic dysfunction in sickle cell disease: lessons from Townes mouse model.

Authors:  Tirthadipa Pradhan-Sundd; Gregory J Kato; Enrico M Novelli
Journal:  Am J Physiol Cell Physiol       Date:  2022-06-27       Impact factor: 5.282

Review 2.  Sickle cell vaso-occlusion: The dialectic between red cells and white cells.

Authors:  Nicola Conran; Stephen H Embury
Journal:  Exp Biol Med (Maywood)       Date:  2021-04-01

Review 3.  Innate immune cells, major protagonists of sickle cell disease pathophysiology.

Authors:  Slimane Allali; Thiago Trovati Maciel; Olivier Hermine; Mariane de Montalembert
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941

4.  P-selectin deficiency promotes liver senescence in sickle cell disease mice.

Authors:  Ravi Vats; Tomasz W Kaminski; Eun-Mi Ju; Tomasz Brozska; Egemen Tutuncuoglu; Jesús Tejero; Enrico M Novelli; Prithu Sundd; Tirthadipa Pradhan-Sundd
Journal:  Blood       Date:  2021-05-13       Impact factor: 25.476

5.  Hemolysis inhibits humoral B-cell responses and modulates alloimmunization risk in patients with sickle cell disease.

Authors:  Mouli Pal; Weili Bao; Rikang Wang; Yunfeng Liu; Xiuli An; William B Mitchell; Cheryl A Lobo; Caterina Minniti; Patricia A Shi; Deepa Manwani; Karina Yazdanbakhsh; Hui Zhong
Journal:  Blood       Date:  2021-01-14       Impact factor: 25.476

6.  The molecular basis for the prothrombotic state in sickle cell disease.

Authors:  Arun S Shet; Maria A Lizarralde-Iragorri; Rakhi P Naik
Journal:  Haematologica       Date:  2020-10-01       Impact factor: 9.941

7.  Inflammatory Dendritic Cells Contribute to Regulate the Immune Response in Sickle Cell Disease.

Authors:  Renata Sesti-Costa; Marina Dorigatti Borges; Carolina Lanaro; Dulcinéia Martins de Albuquerque; Sara Terezinha Olalla Saad; Fernando Ferreira Costa
Journal:  Front Immunol       Date:  2021-02-04       Impact factor: 7.561

Review 8.  Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review.

Authors:  Hiroko Nishida
Journal:  Cancers (Basel)       Date:  2021-05-31       Impact factor: 6.639

Review 9.  CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma.

Authors:  Massimo Martino; Filippo Antonio Canale; Caterina Alati; Iolanda Donatella Vincelli; Tiziana Moscato; Gaetana Porto; Barbara Loteta; Virginia Naso; Massimiliano Mazza; Fabio Nicolini; Andrea Ghelli Luserna di Rorà; Giorgia Simonetti; Sonia Ronconi; Michela Ceccolini; Gerardo Musuraca; Giovanni Martinelli; Claudio Cerchione
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

Review 10.  Intravascular Crawling of Patrolling Monocytes: A Lèvy-Like Motility for Unique Search Functions?

Authors:  Rocío Moreno-Cañadas; Laura Luque-Martín; Alicia G Arroyo
Journal:  Front Immunol       Date:  2021-09-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.